Dianthus Therapeutics Inc (DNTH) Stock AnalysisDNTHStock AnalysisDianthus Therapeutics Inc

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dianthus Therapeutics Inc is currently a hold. The stock is priced at $105.84, which is below the average analyst price target of $125, indicating potential upside. However, the RSI is at 32.032, suggesting it is oversold, and the company reported a significant revenue decline of 99.6% year-over-year, which raises concerns about its market demand and profitability. The main risk is the ongoing net income losses, with a reported net income of -$50,215,000 in Q2 2026, which could impact future financing efforts.